Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2014-11-20 Share Issue/Capital Cha…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Beslut vid extra bolagsstämma i Medivir den 20 november 2014
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Beslut vid extra bolagsstämma i Medivir den 20 november 2014' (Decision at the Extraordinary General Meeting in Medivir on November 20, 2014) and details decisions made regarding a voluntary redemption program ('frivilligt inlösenprogram') involving capital reduction and repayment to shareholders. This relates directly to changes in the company's capital structure and shareholder rights/actions resulting from a general meeting. While it involves capital changes (CAP) and shareholder voting results (DVA), the primary context is the formal decision made at a General Meeting concerning capital structure adjustments. Since the text describes the outcome of a shareholder vote on a specific corporate action (capital reduction/redemption), it aligns closely with the scope of decisions made at general meetings. However, the core action described is a significant capital structure change (inlösenprogram, minskning av aktiekapitalet). Given the options, 'Capital/Financing Update' (CAP) is a strong fit for the redemption program details, but the document explicitly stems from an 'Extra bolagsstämma' (Extraordinary General Meeting). Since the document details the *decision* made at the meeting regarding capital structure, and there isn't a specific code for 'EGM Decision', we must choose the best fit. The action is a capital change (redemption/buyback mechanism). If the document were purely the voting results, DVA would fit. If it were just the announcement of the capital change without the meeting context, CAP would fit. Given the context of a formal decision from a shareholder meeting about a capital structure change, 'CAP' (Capital/Financing Update) captures the substance of the financial action being taken, which is the redemption program. Alternatively, since it is a decision from a general meeting, it is related to AGM-R or DVA, but the content is highly specific to capital structure. I will classify it as CAP as the main subject is the capital redemption program, which is a financing/capital structure event.
2014-11-20 Swedish
Resolutions at the extraordinary general meeting in Medivir on 20 November 2014
Share Issue/Capital Change Classification · 99% confidence The document details resolutions passed at an 'extraordinary general meeting' concerning a 'voluntary redemption programme' involving the reduction of share capital and a bonus issue. This directly relates to changes in the company's capital structure and shareholder rights stemming from a shareholder meeting. While it involves shareholder voting results (DVA) and capital changes (SHA/CAP), the core subject is the formal resolution and execution of a capital structure change (redemption/bonus issue). Since the document describes the outcome of a meeting regarding a capital structure change, 'Capital/Financing Update' (CAP) is the most appropriate fit as it covers capital structure changes, although 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is also relevant for the meeting aspect. Given the focus on the mechanics of the redemption program (repayment amount, record day, application period), CAP is slightly stronger than DVA, which usually just reports the vote tally. However, since it explicitly mentions resolutions at an EGM, DVA is also highly plausible. Given the options, a capital structure change announcement resulting from a meeting is best classified as CAP, as it details the financial mechanics of the change.
2014-11-20 English
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – september 2014' (Interim Report January – September 2014). It contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on business performance, research, and development. It is not a short announcement or a certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report. 9M 2014
2014-11-20 Swedish
Interim / Quarterly Report 2014
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report, January – September 2014'. It contains comprehensive financial statements, including net turnover, operating profit, cash flow, and earnings per share for the specified period. It also includes detailed management commentary, operational highlights, and financial tables. It is not a short announcement or a certification, but the full interim financial report itself. 9M 2014
2014-11-20 English
Olysio® gains additional FDA approval as all-oral treatment in combination with sofosbuvir for treatment of hepatitis C infection
Earnings Release Classification · 95% confidence The document is a press release from Medivir AB announcing an expanded FDA approval for their drug Olysio® (simeprevir) in combination with sofosbuvir for treating hepatitis C. It details the expanded indication, efficacy data from the COSMOS study (SVR12 rates), and adverse reactions. This type of announcement, focusing on key clinical trial results and regulatory milestones (like FDA approval) released via a press release, is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full quarterly/interim report (IR), a full Annual Report (10-K), or a transcript (CT), and it focuses on immediate financial/operational news, it best fits the Earnings Release (ER) category, which covers initial announcements of periodical results or significant operational milestones. Given the context of a major regulatory approval announcement, ER is the most appropriate fit among the provided options for a time-sensitive, results-focused press release. FY 2014
2014-11-06 English
Ytterligare godkännande från den amerikanska läkemedelsmyndigheten för hepatit C-behandling med Olysio® i kombination med sofosbuvir
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that the US FDA has approved an expanded indication for their Hepatitis C treatment, Olysio®, in combination with sofosbuvir. It details clinical trial data (COSMOS study results, SVR12 rates, side effects) and provides regulatory context, concluding with a statement about when the information was made public ('Informationen lämnades för offentliggörande den 6 november 2014, klockan 8.30 CET'). This structure—a formal announcement of a significant business/regulatory event, often including financial or clinical results highlights, but not the full periodic report—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on a specific clinical/regulatory milestone (FDA approval and associated data) rather than general quarterly financial performance highlights (ER), and it is a formal announcement, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if the context implies it was released alongside quarterly results, but RNS is safer for specific regulatory news. Given the content is a specific regulatory approval announcement, RNS is the most appropriate general category for non-standard filings. However, since it contains substantial clinical data and is a major corporate announcement, it could also be considered an Investor Presentation (IP) if it were a slide deck, or a general Regulatory Filing (RNS). Given the format is a press release announcing a regulatory event, RNS is the best fit as a catch-all for significant, non-periodic announcements.
2014-11-06 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.